Literature DB >> 170340

Complete local tumor regression with antibody to fibrin Fragment E.

S I Schlager, S Dray.   

Abstract

Rabbit antibody to fibrin fragment E (FFE) was used in an immunotherapy model for the treatment of the line-10 ascites variant of a diethylnitrosamine-induced hepatoma in strain 2 guinea pigs. When 0.75 or 1.0 mg of an IgG preparation containing anti-FFE antibody was injected s.c. 6 and 16 days after the injection of a uniformly lethal dose of line-10 tumor cells, complete regression of the i.d. growing tumor was observed in all 18 strain 2 guinea pigs treated. Thus, this therapy appears to be more effective than any BCG or other immunotherapeutic regimen thus far reported for this tumor. No significant anti-tumor effect was noted when normal rabbit IgG or smaller doses (0.25 or 0.50 mg) of the anti-FFE IgG preparation were used. The injection sites exhibited an inflammatory response for 7 to 10 days characterized by erythema and hemorrhage. Since all animals were treated after the metastatic progression of the tumor is known to frequently occur, the long-term tumor-free survival of these animals as well as their resistance to subsequent tumor challenge indicate that the anti-FFE antibody therapy led to systemic tumor immunity.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 170340

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  3 in total

1.  Fibrin deposits in Hodgkin's disease.

Authors:  N L Harris; A M Dvorak; J Smith; H F Dvorak
Journal:  Am J Pathol       Date:  1982-07       Impact factor: 4.307

Review 2.  Relationship of tumor leucocytic infiltration to host defense mechanisms and prognosis.

Authors:  J W Kreider; G L Bartlett; B L Butkiewicz
Journal:  Cancer Metastasis Rev       Date:  1984       Impact factor: 9.264

3.  Characterization of factor XIII containing-macrophages in lymph nodes with Hodgkin's disease.

Authors:  R Adány; Z Nemes; L Muszbek
Journal:  Br J Cancer       Date:  1987-04       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.